Published Abstracts and Manuscripts Updated: December 2013 Published Manuscripts 2003 Present Updated: December 2013
Published Manuscripts 2013 Greenberg JD, Spruill TM, Shan Y, Reed G, Kremer JM, Potter J, Yazici Y, Ogedegbe G, Harrold LR. Racial and ethnic disparities in disease activity in patients with rheumatoid arthritis. Am J Med. 2013 Dec;126(12):1089-98. doi: 10.1016/j.amjmed.2013.09.002. Harrold LR, Reed GW, Kremer JM, Curtis JR, Solomon DH, Hochberg MC, Greenberg JD. The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor. Ann Rheum Dis. 2013 Dec 2. doi: 10.1136/annrheumdis-2013-203936. [Epub ahead of print] Solomon DH, Kremer JM, Fisher M, Curtis JR, Furer V, Hochberg MC, Reed G, Tsao P, Greenberg JD. Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs. Seminars in arthritis and rheumatism 2013 doi: 10.1016/j.semarthrit.2013.08.003[Epub ahead of print] Labitigan M, Bahce-Altuntas A, Kremer JM, Reed G, Greenberg JD, Jordan N, Putterman C, Broder A. Higher rates and clustering of abnormal lipids, obesity, and diabetes in psoriatic arthritis compared with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2013 Oct 7. doi: 10.1002/acr.22185. [Epub ahead of print] McAllister K, Yarwood A, Bowes J, Orozco G, Viatte S, Diogo D, Hocking LJ, Steer S, Wordsworth P, Wilson AG, Morgan AW; UK Rheumatoid Arthritis Genetics Consortium; Rheumatoid Arthritis Consortium International, Kremer J, Pappas D, Gregersen P, Klareskog L, Plenge R, Barton A, Greenberg J, Worthington J, Eyre S. Meta-analysis identifies BACH2 and RAD51B as rheumatoid arthritis susceptibility loci. Arthritis Rheum 2013 Sep 10. doi: 10.1002/art.38183[Epub ahead of print] Yarwood A, Han B, Raychaudhuri S, Bowes J, Lunt M, Pappas DA, Kremer J, Greenberg JD, Plenge R; Rheumatoid Arthritis Consortium International (RACI), Worthington J, Barton A, Eyre S. A weighted genetic risk score using all known susceptibility variants to estimate rheumatoid arthritis risk. Ann Rheum Dis. 2013 Oct 3. [Epub ahead of print] Harrold LR, Reed GW, Kremer JM, Curtis JR, Solomon DH, Hochberg MC, Greenberg JD. The Comparative Effectiveness of Abatacept versus Anti-Tumor Necrosis Factor Switching for Rheumatoid Arthritis Patients Previously Treated with an Anti-Tumor Necrosis Factor. Ann Rheum Dis. 2013 Dec 2. doi: 10.1136/annrheumdis-2013-203936. [Epub ahead of print] Curtis JR, Shan Y, Harrold L Zhang J, Greenber JD, Reed GW. Patient perspectives on achieving T2T goals: A critical examination of patient reported outcomes. Arthritis care & research 2013;65(10):1707-12 doi: 10.1002/acr.22048.Published Online First: 5 June 2013 Dewitt, EM, Li Y, Curtis JR, Glick HA, Greenberg JD, Anstrom KJ, Kremer JM, Reed G, Schulman KA, Reed SD. Comparative Effectiveness of Nonbiologic versus Biologic Disease Modifying
Antirheumatic Drugs for Rheumatoid Arthritis. The Journal of rheumatology 2013;40(2):127-36 doi: 10.3899/jrheum.120400J Diogo D, Kurreeman F, Stahl EA, Liao KP, Gupta N, Greenberg JD, Rivas MA, Hickey B, Flannick J, Thomson B, Guiducci C, Ripke S, Adzhubev I, Barton A, Kremer JM, Aldfredsson L; Consortium of Rheumatology Researchers of North America; Rheumatoid Arthritis Consortium International, Sunyaev S, Martin J, Zhernakova A, Bowes J, Eyre S, Siminovitch KA, Gregersen PK, Worthington J, Klareskog L, Padyukov L, Raychaudhuri S, Plenge RM. Rare, Low-Frequency, and Common Varients in the Protein-Coding Sequence of Biological Candidate Genes from GWASs Contribute to Risk of Rheumatoid Arthritis. Am J Hum Genet. 2013 Jan 10;92(1):15-27. doi: 10.1016/j.ajhg.2012.11.012. Epub 2012 Dec 20. Sarsour K, Greenberg JD, Johnston JA, Nelson DR, O Brien LA, Oddoux C, Ostrer H, Pearlman A, Reed G. The Role of the FcGRIIIa Polymorphism in Modifying the Association Between Treatment and Outcome in Patients with Rheumatoid Arthritis Treated with Rituximab Versus TNF-α antagonist therapies. Clin Exp Rheumatol. 2013 Mar- Apr 3; 31(2): 189-94. Epub 2013 Jan 9. 2012 Pappas DA, Oh C, Plenge RM, Kremer JM, Greenberg JD. Association of Rheumatoid Arthritis Risk Alleles with Response to Anti-TNF Biologics: Results from the CORRONA Registry and Meta-analysis. Inflammation. Inflammation 2013;36(2):279-84 doi: 10.1007/s10753-012-9544-4. [Epub ahead of print] PubMed PMID: 23007924. Greenberg JD, Reed G, Decktor D, Harrold L, Furst D, Gibofsky A, Dehoratius R, Kishimoto M, Kremer JM; CORRONA Investigators. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis. 2012 Jul;71(7):1134-42. Epub 2012 Jan 30. PubMed PMID: 22294625. Jawaheer D, Messing S, Reed G, Ranganath VK, Kremer JM, Louie JS, Khanna D, Greenberg JD, Furst DE. Significance of sex in achieving sustained remission in the Consortium of Rheumatology Researchers of North America cohort of rheumatoid arthritis patients Arthritis care & research 2012;64(12):1811-8 doi: 10.1002/acr.21762. PubMed PMID: 22730408. Fisher MC, Hochberg MC, El-Taha M, Kremer JM, Peng C, Greenberg JD; CORRONA Investigators. Smoking, smoking cessation, and disease activity in a large cohort of patients with rheumatoid arthritis. J Rheumatol. 2012 May;39(5):904-9. Epub 2012 Mar 15. PubMed PMID: 22422494. Fisher MC, Furer V, Hochberg MC, Greenberg JD, Kremer JM, Curtis JR,Reed G, Harrold L, Solomon DH. Malignancy validation in a United States registry of rheumatoid arthritis patients. BMC Musculoskelet Disord. 2012 May 31;13:85. Harrold LR, Harrington JT, Curtis JR, Furst DE, Bentley MJ, Shan Y, Reed G, Kremer J, Greenberg JD. Prescribing practices in a US cohort of rheumatoid arthritis patients before and after publication of the American College of Rheumatology treatment recommendations. Arthritis Rheum. 2012 Mar;64(3):630-8. doi: 10.1002/art.33380. PubMed PMID: 21953645; PubMed
Central PMCID: PMC3253907. Solomon DH, Mercer E, Kavanaugh A. Observational Studies on the Risk of Cancer Associated With Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis. Arthritis Rheum. 2012 January; 64 (1): 21-32. DOI 10.1002/art.30653 2011 Anandarajah AP, El-Taha M, Peng C, Reed G, Greenberg JD, Ritchlin CT. Association between focal erosions and generalized bone loss in psoriatic arthritis. Ann Rheum Dis. 2011 Jul;70(7):1345-7. Epub 2011 Feb 16. Au K, Reed GW, Curtis JR, Kremer JM, Greenberg JD, Strand V, Furst DE. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis. 2011 May;70(5):785-791. Epub 2011 Feb 2. Furst DE, Pangan AL, Harrold LR, Chang H, Reed G, Kremer JM, Greenberg JD. Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from the consortium of rheumatology researchers of North America registry. Arthritis Care Res (Hoboken). 2011 Jun;63(6):856-64. Greenberg JD, Kremer JM, Curtis JR, Hochberg MC, Reed GW, Tsao P, Farkouh ME, Nasir A, Setoguchi S, Solomon DH. Tumor necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis. 2011 Apr;70(4):576-582. Epub 2010 Nov 24. Zhang J, Shan Y, Reed G, Kremer J, Greenberg JD, Baumgartner S, Curtis JR: Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: experience from a large U.S. cohort. Arthritis care & research 2011, 63(12):1672-1679. 2010 Reddy S, Anandarajah A, Fisher M, Mease P, Greenberg J, Kremer J, Reed G, Chen R, Messing S, Kaukenien, K, Ritchlin CT. Comparative analysis of disease activity measures using biologic agents, BMI, Radiographic Features, and Bone Density in Psoriatic Arthritis and Rheumatoid Arthritis Patients Followed in a Large US Disease Registry. Journal of Rheumatology. 2010 Dec; 37(12): 2566-72. Sokolove J, Strand V, Greenberg JD, Curtis JR, Kavanaugh A, Kremer JM, Anofrei A, Reed R, Calabrese L, Hooper M, Baumgertner S, and Furst D. Risk of elevated liver enzymes associated with TNF inhibitor utilization in patients with rheumatoid arthritis. Ann Rheum Dis. 2010 Sep; 69(9): 1612-7. Curtis JR, Jain A, Askling J, et al. A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Seminars in arthritis and rheumatism. Aug 2010;40(1):2-14 e11.
Bentley MJ, Greenberg JD, Reed GW. A modified rheumatoid arthritis disease activity score without acute-phase reactants (mdas28) for epidemiological research. J Rheumatology. 2010 Aug 1;37(8):1607-14 Solomon DH, Kremer JM, Curtis JR, Hochberg M, Reed G, Tsao P, Farkouh M, Setoguch S, and Greenberg JD. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional Risk Factors Versus Markers of Rheumatoid Arthritis Severity. Ann Rheum Dis. 2010 Nov;69(11):1920-5. Epub 2010 May 5. Greenberg JD, Reed G, Kremer JM, Tindall E, Kavanaugh A, Zheng C, Bishai W, Hochberg M. Association of methotrexate and tumor necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis. 2010 Feb;69(2):380-6. Curtis JR, Chen L, Harrold LR, Narongroeknawin P, Reed G, Solomon DH. Physician preference motivates the use of anti-tumor necrosis factor therapy independent of clinical disease activity. Arthritis Care Res. 2010 Jan 15;62(1):101-7. Curtis JR, Beukelman T, Onofrei A, Strand V, Greenberg JD, Reed G, Kremer JM. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. Annals of Rheumatic Disease 2010 Jan; 69(1):43-7. 2009 Kremer JM, Greenberg JD. Interpreting registry derived drug studies: does societal context matter? Arthritis Rheum. 2009 Nov; 60(11):3155-7. Curtis JR, Patkar NM, Jain A, Greenberg J, Solomon DH. The validity of physician-reported hospitalized infections in an observational U.S. arthritis registry. Rheumatology (Oxford) 2009 October; 48(10):1269-72. Lee SJ, Chang H, Yazici Y, Greenberg JD, Kremer JM, Kavanaugh A. Utilization trends of tumor necrosis factor inhibitors among rheumatoid arthritis patients in a United States observational cohort study. J Rheumatol. 2009 Aug; 36(8):1611-7. Furst D, Chang H, Greenberg J, Ranganath V, Reed G, Ozturk Z, Kremer JM. Prevalence of low hemoglobin levels and associations with other disease parameters in rheumatoid arthritis patients: Evidence from the CORRONA registry. Clin Exp Rheumatol. 2009 Jul-Aug;27(4): 560-6. Greenberg JD, Fisher MC, Kremer JM, Chang H, Rosenstein ED, Kishimoto M, Lee S, Yazici Y, Kavanaugh A, Abramson SB. The COX-2 inhibitor market withdrawals and prescribing patterns by rheumatologists in patients with gastrointestinal and cardiovascular risk. Clin Exp Rheumatol. 2009 May-Jun; 27(3):395-401. Greenberg JD, Harrold LR, Bentley MJ, Kremer JM, Reed G. Strand V. Evaluation of composite measures of treatment response without acute phase reactants in patients with rheumatoid arthritis. Rheumatology (Oxford). 2009 June; 48(6):686-90
Coulson KA, Reed G, Gilliam BE, Kremer JM, Pepmueller PH. Factors influencing fracture risk, T score, and management of osteoporosis in patients with rheumatoid arthritis in the Consortium of Rheumatology Researchers of North America (CORRONA) registry. J Clin Rheumatol. 2009 Jun;15(4):155-60. 2008 Aizer J, Reed G, Onofrei A, Harrison MJ. Predictors of bone density testing in patients with rheumatoid arthritis. Rheumatology international. Jun 2009;29(8):897-90 Ranganath VK, Paulus HE, Onofrei A, Khanna D, Reed G, Elashoff DA, Kremer JM, Furst DE. Functional improvement after patients with rheumatoid arthritis start a new disease modifying antirheumatic drug (DMARD) associated with frequent changes in DMARD: the CORRONA database. J Rheumatol. 2008 Oct;35(10):1966-71. Greenberg JD, Kishimoto M, Strand V, Cohen SB, Olenginski TP, Harrington JT, Kafka SP, Reed G, Kremer JM. TNF antagonist responsiveness in a United States rheumatoid arthritis cohort. Am J Med. 2008 June;121(6):532-538. Kremer JM, Gibofsky A, Greenberg JD. The role of drug and disease registries in rheumatic disease epidemiology. Current Opinion in Rheumatology. 2008 March;20(2):123 130. 2006 Tutuncu Z, Reed G, Kremer JM, Kavanaugh A. Do patients with older-onset rheumatoid arthritis receive less aggressive treatment? Ann Rheum Dis. 2006 Sep;65(9):1226-1229 Greenberg JD, Bingham CO, Abramson SB, Reed G, Kishimoto M, Hinkle K, Kremer JM. Assessment of coxib utilization by rheumatologists for nonsteroidal antiinflammatory drug gastroprotection prior to the coxib market withdrawals. Arthritis Rheum (Arthritis Care and Research), Aug 2006;55(4):543-50. Kremer JM. The CORRONA Database. Autoimmun Rev. 2006 Jan;5(1):46-54. 2005 Kremer JM. The CORRONA Database. Ann Rheum Dis. 2005 Nov;64 Suppl 4:iv37-41. Kremer JM. The CORRONA Database. Clin Exp Rheumatol. 2005 Sep-Oct;23(5 Suppl 39):S172-7. Greenberg JD, Bingham CO, Abramson SB, Reed G, Seibaldt R, Kremer JM. Effect of cardiovascular comorbidities and concomitant aspirin use onselection of cyclooxgenase inhibitor among rheumatologists. Arthritis Rheum (Arthritis Care and Research), 2005 Feb;53:12-17 2003
Sebaldt RJ, Kremer JM. CANDOO and CANOAR, CORRONA and more: advancing therapeutics through layered-in clinical data collection and feedback at the point of care. The Journal of rheumatology. Nov 2003;30(11):2308-2311.